CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

CHAMPIONS ONCOLOGY, INC.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026

$4.69−0.01 (-0.21%)

Close on Oct 19, 2026

Market cap: $65.18M
P/E (TTM): –
Dividend yield: –

CHAMPIONS ONCOLOGY, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-04-30	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30	FY 2020 2020-04-30	FY 2019 2019-04-30	FY 2018 2018-04-30	FY 2017 2017-04-30	FY 2016 2016-04-30	FY 2015 2015-04-30	FY 2014 2014-04-30	FY 2013 2013-04-30	FY 2012 2012-04-30	FY 2011 2011-04-30
Revenue	59	57	50	54	49	41	32	2.90	20	15	11	8.86	12	8.32	7.15	6.88
Cost of Revenue	31	28	29	30	24	21	17	–	–	–	–	–	–	–	–	–
Gross Profit	29	29	21	24	25	20	15	–	–	–	–	–	–	–	–	–
Research & Development	9.08	6.83	9.54	12	9.37	7.20	5.85	4.80	4.40	4.29	4.19	4.85	2.27	1.92	2.94	2.91
Selling, General & Admin	20	17	18	17	15	12	11	7.73	6.64	8.22	8.62	9.62	9.28	7.30	8.38	5.70
Selling & Marketing	9.32	7.55	7.06	7.00	6.38	5.52	4.24	3.06	2.57	3.26	3.45	4.28	3.16	2.67	2.93	1.09
General & Administrative	11	9.34	11	10	9.12	6.51	6.61	4.68	4.07	4.96	5.17	5.34	6.13	4.63	5.45	4.61
Advertising Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	0.05	0.14	–
Operating Expenses	–	–	–	–	–	–	34	27	22	22	21	22	18	15	16	12
Operating Income	-1.14	4.55	-7.36	-5.26	0.61	0.37	-1.92	0.27	-1.35	-6.81	-10	-13	-6.26	-6.22	-9.07	-5.24
Other Non-Operating Income	0.21	0.07	0.05	-0.01	-0.02	0.07	-0.04	-0.04	-0.09	-0.06	-0.04	0.23	-1.13	-0.10	0.40	1.44
Asset Impairment Charges	0	0	0	0	0	0	0.34	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.11	-0.29	-0.44	0	0.00	0	0.05	0	0.00	–	0	-0.01	0	–	0	0.00
Pretax Income	-0.93	4.63	-7.31	-5.27	0.58	0.44	-1.96	0.23	-1.44	-6.87	-10	-13	-7.39	-6.32	-8.66	-3.79
Income Tax Expense	0.25	-0.08	-0.03	0.07	0.04	0.08	0.13	0.10	0.03	0.02	0.09	0.13	0.02	0.01	0.00	0.01
Net Income incl. Noncontrolling Interests	-1.18	4.70	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-1.18	4.70	-7.28	-5.34	0.55	0.36	-2.09	0.13	-1.48	-6.88	-10	-13	-7.41	-6.33	-8.66	-3.80
Net Income to Common	-1.18	4.70	-7.28	-5.34	0.55	0.36	-2.09	0.13	-1.48	–	-10	-14	-7.41	–	–	–
EPS (Basic)(per share)	-0.08	0.34	-0.54	-0.39	0.04	0.03	-0.18	0.01	-0.13	-0.64	-1.20	-2.20	-1.32	-1.44	-2.28	-1.32
EPS (Diluted)(per share)	-0.08	0.33	-0.54	-0.39	0.04	0.02	-0.18	0.01	-0.13	-0.64	-1.20	-2.20	-1.32	-1.44	-2.28	-1.32
Shares Outstanding (Basic, Weighted)(shares)	14	14	14	14	13	13	12	11	11	11	8.70	5.99	5.57	4.34	3.90	–
Shares Outstanding (Diluted, Weighted)(shares)	14	14	14	14	14	15	12	14	11	11	8.70	6.42	5.57	4.34	3.90	–
EBITDA	0.26	6.15	-5.46	-3.16	2.11	1.29	-1.10	0.88	-0.99	-6.64	-10	-13	-6.05	-6.02	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: 49.8%
Operating margin: -1.7%
Net margin: -1.8%
Return on equity, FY2026: -30.5%

Financial strength

Current ratio: 1.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 23.3%

Valuation

P/E ratio: –
Price to sales: 1.07
Price to book: 16.74
Dividend yield: –